Elsevier

Blood Reviews

Volume 13, Issue 2, June 1999, Pages 91-104
Blood Reviews

Microbiology confirmatory tests for blood donors

https://doi.org/10.1016/S0268-960X(99)90015-2Get rights and content

Abstract

Blood donations collected in Scotland are currently screened for the presence of HBsAg, anti-HIV 1 + 2, anti-HCV and syphilis antibodies. Approximately 1% of all donations are found to repeatedly react to one of these four markers on screening but very few represent true infection. These samples must be sent to the designated confirmatory laboratory whose main role is to identify the true positive amongst a sea of ‘false positives’. A battery of tests is used for this purpose, usually applied in a defined sequence. The use of such ‘confirmatory algorithms’ for each marker has been developed by most countries over the years and is now essential to the confirmatory process. The advent of gene amplification techniques such as PCR for initially pooled and eventually single donation testing will be the next challenge for confirmatory laboratories and will demand standards of confirmation as accurate as currently performed with the present serological markers.

References (52)

  • M. Ferguson et al.

    Working standards for hepatitis B surface antigen for use in the UK blood transfusion service: results of a collaborative study

    Vox Sang

    (1993)
  • A. Raafat et al.

    Benefit of dynamic over static incubation in the detection of a low level HBsAg (chronic carrier) bone donor

    Vox Sang

    (1998)
  • B.C. Dow et al.

    Several assays show hepatitis B positivity soon after vaccination

    Br Med J

    (1998)
  • W. Hughes et al.

    A multicentre assessment of the specificity of ten anti-HBe screening tests

    Transfus Med

    (1995)
  • A. Barr et al.

    Hepatitis B virus markers in blood donors in the west of Scotland

    Med Lab Sci

    (1981)
  • F. McOmish et al.

    Detection of three types of hepatitis C virus in blood donors: investigation of type-specific differences in serologic reactivity and rate of alanine aminotransferase abnormalities

    Transfusion

    (1993)
  • S.W. Chan et al.

    Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants

    J Gen Virol

    (1992)
  • F. McOmish et al.

    Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey

    J Clin Microbiol

    (1994)
  • B.C. Dow et al.

    Comparison of second and third generation hepatitis C virus enzyme-linked immunosorbent assays in a low-risk blood donor population

    Transfusion

    (1996)
  • P.E. Hewitt et al.

    Unexplained hepatitis C virus antibody seroconversion in established blood donors

    Transfusion

    (1997)
  • K. Soldan et al.

    Incidence of seroconversion to positivity for hepatitis C antibody in repeat blood donors, in England, 1993–1995

    Br Med J

    (1998)
  • B.C. Dow et al.

    Relevance of RIBA-3 supplementary test to HCV PCR positivity and genotypes for HCV confirmation in blood donors

    J Med Virol

    (1996)
  • F. Davidson et al.

    Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5′ non-coding region

    J Gen Virol

    (1995)
  • V. Bhattarcherjee et al.

    Use of NS-4 peptides to identify type-specific antibody to hepatitis C virus genotypes l, 2, 3, 4, 5 and 6.

    J Gen Virol

    (1995)
  • V. Dixit et al.

    Evaluation of a novel serotyping system for hepatitis C virus: strong correlation with standard genotyping methodologies

    J Clin Micrbiol

    (1995)
  • B.C. Dow et al.

    Failure of 2nd- and 3rd-generation HCV ELISA and RIBA to detect HCV polymerase chain reaction-positive donations

    Vox Sang

    (1994)
  • Cited by (15)

    • Evaluation of serological transfusion-transmitted viral diseases and mutliplex nucleic acid testing in malaysian blood donors

      2013, Transfusion and Apheresis Science
      Citation Excerpt :

      We found that the majority of discrepant reactive results reacted with anti-HCV antibodies but were negative by NAT and confirmatory testing (INNO-LIA test). The possible explanations for “False Reactive” results via Serological false positive reactivity might be due to either cross-reactivity or contaminants in coating antigens, or to levels of DNA / RNA concentrations in specimens tested that were below detectable limits by molecular test [6,19,20]. Some patients with discrepant serology vs. NAT results might be “biological false positives” who have cleared their infections while others are “analytic” false positives that, in the absence of past infection, have positive serology due to cross-reactivity or other factors that reduce the specificity of the assay [21,22].

    View all citing articles on Scopus
    View full text